

Special Issue

Delivery Systems of Plasmid DNA and Messenger RNA for Advanced Therapies

Message from the Guest Editor

The delivery of plasmid DNA (pDNA) and messenger RNA (mRNA) is garnering growing attention as the next generation of therapeutics for intractable diseases, including genetic diseases and cancers. Vaccines against pandemic diseases and cancers are also promising targets of this approach. Indeed, several clinical trials are in progress. Concurrently, basic studies are vigorously performed to improve gene introduction efficiency and minimize toxicity concerns of the delivery systems, by developing novel delivery carriers of pDNA and mRNA and applying them for therapeutic studies in animal models. These efforts are valuable for overcoming the current limitations of non-viral gene therapy to achieve the widespread application of pDNA and mRNA therapeutics in the future. This Special Issue welcomes your contribution in these fields at various stages, from the development of delivery systems to the therapeutic application of the systems, in the form of communications, original articles and reviews.

Guest Editor

Prof. Dr. Satoshi Uchida

Medical Chemistry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Deadline for manuscript submissions

closed (10 November 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/61089

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).